Global Induced Pluripotent Stem Cell Market to 2026 – Featuring Axol Bioscience, Evotec and Fate Therapeutics Among Others – ResearchAndMarkets.com

Global Induced Pluripotent Stem Cell Market to 2026 – Featuring Axol Bioscience, Evotec and Fate Therapeutics Among Others – ResearchAndMarkets.com




Global Induced Pluripotent Stem Cell Market to 2026 – Featuring Axol Bioscience, Evotec and Fate Therapeutics Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Induced Pluripotent Stem Cell (iPSC) – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Induced Pluripotent Stem Cell (iPSC) estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2026, growing at a CAGR of 6.6% over the analysis period.

Vascular Cells, one of the segments analyzed in the report, is projected to record a 7.2% CAGR and reach US$835.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiac Cells segment is readjusted to a revised 7.9% CAGR for the next 7-year period. The demand for iPSC-derived cardiac cells is attributed to diverse applications including cardiotoxicity testing, drug screening and drug validation along with metabolism studies and electrophysiology applications.

The U.S. Market is Estimated at $767.1 Million in 2021, While China is Forecast to Reach $82.4 Million by 2026

The Induced Pluripotent Stem Cell (iPSC) market in the U.S. is estimated at US$767.1 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.4 Million by the year 2026 trailing a CAGR of 8.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5 % and 6.8% respectively over the analysis period.

Within Europe, Germany is forecast to grow at approximately 6.5% CAGR. North America leads the global market, supported by continuing advances related to iPSC technology and access to functional cells used in pre-clinical drug screening. The market growth is supplemented by increasing insights into the iPSC platform along with high throughput analysis for drug toxicity. The iPSC market in Asia-Pacific is estimated to post a fast growth due to increasing R&D projects across countries like Australia, Japan and Singapore.

Select Competitors (Total 51 Featured) –

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Induced Pluripotent Stem Cells (iPSCs) Market Gains from Increasing Use in Research for COVID-19
  • Studies Employing iPSCs in COVID-19 Research
  • Stem Cells, Application Areas, and the Different Types: A Prelude
  • Applications of Stem Cells
  • Types of Stem Cells
  • Induced Pluripotent Stem Cell (iPSC): An Introduction
  • Production of iPSCs
  • First & Second Generation Mouse iPSCs
  • Human iPSCs
  • Key Properties of iPSCs
  • Transcription Factors Involved in Generation of iPSCs
  • Noteworthy Research & Application Areas for iPSCs
  • Induced Pluripotent Stem Cell (iPSC) Market: Growth Prospects and Outlook
  • Drug Development Application to Witness Considerable Growth

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
  • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
  • Research Trends in Induced Pluripotent Stem Cell Space
  • Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
  • Number of Original Research Papers on hESC and iPSC Published Worldwide (2014-2016)
  • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
  • Regenerative Medicine: A Promising Application of iPSCs
  • Induced Pluripotent: A Potential Competitor to hESCs?
  • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Global Stem Cell & Regenerative Medicine Market by Product (in %) for the Year 2019
  • Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
  • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
  • Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
  • Leading Causes of Mortality for Low-Income and High-Income Countries
  • Growing Importance of iPSCs in Personalized Drug Discovery
  • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
  • Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
  • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
  • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/7m105p

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900